Immunosuppression for inflammatory bowel disease does not influence Epstein-Barr viral load in the short-term

Rodríguez-Lago, Iago; Merino, Olga; López de Goicoechea, María José; Aranzamendi, Maitane; Zubiaurre, Leire; Muro, Nerea; Ortiz de Zárate, Jone; Cilla, Gustavo; Cabriada, José Luis.
Gastroenterol. hepatol. (Ed. impr.) ; 42(9): 542-547, nov. 2019. tab
Artículo en Inglés | IBECS (España) | ID: ibc-187915

Documentos relacionados

  1. Immunosuppression for inflammatory bowel disease does not influence Epstein-Barr viral load in the short-term.
  2. Clinical and endoscopic complications of Epstein-Barr virus in inflammatory bowel disease: an illustrative case series.
  3. Impact of Epstein-Barr virus infection on inflammatory bowel disease (IBD) clinical outcomes.
  4. The Status of Epstein-Barr Virus Infection in Intestinal Mucosa of Chinese Patients with Inflammatory Bowel Disease.
  5. Increasing ratio of opportunistic infections associated with sunshine exposure and economic level burdening Chinese inflammatory bowel disease hospitalized patients: the first nationwide survey from 2014 to 2019.
  6. Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases.
  7. Chronic active Epstein-Barr virus infection involving gastrointestinal tract mimicking inflammatory bowel disease.
  8. EBV-associated lymphoproliferative disorder involving the gastrointestinal tract which mimic IBD in immunocompetent patients: case reports and literature review.
  9. EBV Status and Thiopurine Use in Pediatric IBD.
  10. SERO-PREVALENCE OF EPSTEIN-BARR VIRUS IN IRAQI INFLAMMATORY BOWEL DISEASE.